Clinical outcomes of an innovative cefazolin delivery program for MSSA infections in OPAT

Cefazolin is a recommended treatment for methicillin-susceptible Staphylococcus aureus (MSSA) infections that has been successfully used in outpatient parenteral antibiotic therapy (OPAT) programs. The aim of this study was to assess the clinical outcomes of cefazolin delivered each day (Group 24) v...

Descripción completa

Detalles Bibliográficos
Autores: Herrera Hidalgo, Laura, Luque Márquez, Rafael, Alarcón, Arístides de, Guisado Gil, Ana Belén, Gutiérrez Gutiérrez, Belén, Navarro Amuedo, María Dolores, Gil Navarro, María Victoria
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/137930
Acceso en línea:https://hdl.handle.net/11441/137930
https://doi.org/10.3390/jcm11061551
Access Level:acceso abierto
Palabra clave:Methicillin-susceptible Staphylococcus aureus
MSSA
OPAT
Cefazolin
Home-delivery
id ES_8b520ba01d062dad6d3bfd0a6427cb6b
oai_identifier_str oai:idus.us.es:11441/137930
network_acronym_str ES
network_name_str España
repository_id_str
spelling Clinical outcomes of an innovative cefazolin delivery program for MSSA infections in OPATHerrera Hidalgo, LauraLuque Márquez, RafaelAlarcón, Arístides deGuisado Gil, Ana BelénGutiérrez Gutiérrez, BelénNavarro Amuedo, María DoloresGil Navarro, María VictoriaMethicillin-susceptible Staphylococcus aureusMSSAOPATCefazolinHome-deliveryCefazolin is a recommended treatment for methicillin-susceptible Staphylococcus aureus (MSSA) infections that has been successfully used in outpatient parenteral antibiotic therapy (OPAT) programs. The aim of this study was to assess the clinical outcomes of cefazolin delivered each day (Group 24) vs. every two days (Group 48) for MSSA infections in OPAT programs. It was a prospective observational study with retrospective analysis of a cohort of MSSA infections attended in OPAT. The primary outcome was treatment success, defined as completing the antimicrobial regimen without death, treatment discontinuation, or readmission during treatment and follow-up. A univariate and multivariate logistic regression model was built. A two-sided p < 0.05 was considered statistically significant. Of the 149 MSSA infections treated with cefazolin 2 g/8 h in OPATs, 94 and 55 patients were included in the delivery Group 24 and Group 48, respectively. Treatment failure and unplanned readmission rates were similar in both groups (11.7% vs. 7.3% p = 0.752 and 8.5% vs. 5.5% p = 0.491). There was a significant increase in vascular access complications in Group 24 (33.0%) with respect to Group 48 (7.3%) (p < 0.001). Treating uncomplicated MSSA infection with cefazolin home-delivered every two days through an OPAT program is not associated with an increased risk of treatment failure and entails a significant reduction in resource consumption compared to daily delivery.MDPIMedicina2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/137930https://doi.org/10.3390/jcm11061551reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésJournal of Clinical Medicine, 11 (6), 1-11.https://www.mdpi.com/2077-0383/11/6/1551info:eu-repo/semantics/openAccessoai:idus.us.es:11441/1379302026-06-17T12:51:07Z
dc.title.none.fl_str_mv Clinical outcomes of an innovative cefazolin delivery program for MSSA infections in OPAT
title Clinical outcomes of an innovative cefazolin delivery program for MSSA infections in OPAT
spellingShingle Clinical outcomes of an innovative cefazolin delivery program for MSSA infections in OPAT
Herrera Hidalgo, Laura
Methicillin-susceptible Staphylococcus aureus
MSSA
OPAT
Cefazolin
Home-delivery
title_short Clinical outcomes of an innovative cefazolin delivery program for MSSA infections in OPAT
title_full Clinical outcomes of an innovative cefazolin delivery program for MSSA infections in OPAT
title_fullStr Clinical outcomes of an innovative cefazolin delivery program for MSSA infections in OPAT
title_full_unstemmed Clinical outcomes of an innovative cefazolin delivery program for MSSA infections in OPAT
title_sort Clinical outcomes of an innovative cefazolin delivery program for MSSA infections in OPAT
dc.creator.none.fl_str_mv Herrera Hidalgo, Laura
Luque Márquez, Rafael
Alarcón, Arístides de
Guisado Gil, Ana Belén
Gutiérrez Gutiérrez, Belén
Navarro Amuedo, María Dolores
Gil Navarro, María Victoria
author Herrera Hidalgo, Laura
author_facet Herrera Hidalgo, Laura
Luque Márquez, Rafael
Alarcón, Arístides de
Guisado Gil, Ana Belén
Gutiérrez Gutiérrez, Belén
Navarro Amuedo, María Dolores
Gil Navarro, María Victoria
author_role author
author2 Luque Márquez, Rafael
Alarcón, Arístides de
Guisado Gil, Ana Belén
Gutiérrez Gutiérrez, Belén
Navarro Amuedo, María Dolores
Gil Navarro, María Victoria
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Medicina
dc.subject.none.fl_str_mv Methicillin-susceptible Staphylococcus aureus
MSSA
OPAT
Cefazolin
Home-delivery
topic Methicillin-susceptible Staphylococcus aureus
MSSA
OPAT
Cefazolin
Home-delivery
description Cefazolin is a recommended treatment for methicillin-susceptible Staphylococcus aureus (MSSA) infections that has been successfully used in outpatient parenteral antibiotic therapy (OPAT) programs. The aim of this study was to assess the clinical outcomes of cefazolin delivered each day (Group 24) vs. every two days (Group 48) for MSSA infections in OPAT programs. It was a prospective observational study with retrospective analysis of a cohort of MSSA infections attended in OPAT. The primary outcome was treatment success, defined as completing the antimicrobial regimen without death, treatment discontinuation, or readmission during treatment and follow-up. A univariate and multivariate logistic regression model was built. A two-sided p < 0.05 was considered statistically significant. Of the 149 MSSA infections treated with cefazolin 2 g/8 h in OPATs, 94 and 55 patients were included in the delivery Group 24 and Group 48, respectively. Treatment failure and unplanned readmission rates were similar in both groups (11.7% vs. 7.3% p = 0.752 and 8.5% vs. 5.5% p = 0.491). There was a significant increase in vascular access complications in Group 24 (33.0%) with respect to Group 48 (7.3%) (p < 0.001). Treating uncomplicated MSSA infection with cefazolin home-delivered every two days through an OPAT program is not associated with an increased risk of treatment failure and entails a significant reduction in resource consumption compared to daily delivery.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/137930
https://doi.org/10.3390/jcm11061551
url https://hdl.handle.net/11441/137930
https://doi.org/10.3390/jcm11061551
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Journal of Clinical Medicine, 11 (6), 1-11.
https://www.mdpi.com/2077-0383/11/6/1551
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412800313425920
score 15,301603

Similares en LA Referencia